[-] Show simple item record

dc.contributor.authorHuntington, Janeeng
dc.contributor.authorZantop, Veronikaeng
dc.date.issued2004-12eng
dc.description.abstractSelective serotonin reuptake inhibitors (SSRIs) are considered first-line agents for the treatment of depression in pregnant women. SSRIs and tricyclic antidepressants (TCAs) are considered safe and effective in pregnant women, although some studies have indicated increased short-term neonatal adverse effects after exposure to antidepressants in the third trimester.[Strength of recommendation: B, based on cohort studies.]eng
dc.identifier.citationAmerican Family Physician, 70(11) 2004.eng
dc.identifier.urihttp://hdl.handle.net/10355/3930eng
dc.languageEnglisheng
dc.publisherFamily Physicians Inquiries Networkeng
dc.relation.ispartofClinical Inquiries, 2004 (MU)eng
dc.relation.ispartofcommunityUniversity of Missouri-Columbia. School of Medicine. Department of Family and Community Medicine. Family Physicians Inquiries Networkeng
dc.rightsOpenAccess.eng
dc.rights.licenseThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License.eng
dc.subjectneonatal toxicityeng
dc.subjectantidepressant therapyeng
dc.subjectneonatal withdrawal syndromeeng
dc.subject.lcshAntidepressantseng
dc.subject.lcshObstetrical pharmacologyeng
dc.subject.lcshFetus -- Effect of drugs oneng
dc.subject.lcshNewborn infants -- Effect of drugs oneng
dc.subject.lcshPregnant women -- Drug useeng
dc.subject.meshMaternal-Fetal Exchange -- drug effectseng
dc.titleAntidepressant Medications in Pregnancyeng
dc.typeArticleeng


Files in this item

[PDF]

This item appears in the following Collection(s)

[-] Show simple item record